Tag: 56

Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million

Management to Hold Call Following Market Close Today

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision Biologics, Danaher Corporation (Cepheid Inc.), GE HealthCare, Celera Diagnostics LLC, Decode Genetics Inc., Exact Sciences Corporation, IBM Corporation, Exagen Inc., Biogen, QIAGEN, Genentech Inc., 23andMe Inc., Asuragen Inc and others.

– Total Revenues increased 13.8% for the quarter over the prior year period to $60.3 million –
– Total Written Premium increased 14.4% for the quarter over the prior year period to $450.3 million –
– Organic Revenue Growth Rate* of 10.6% for the quarter –
– Net income of $9.0 million for the quarter –
– Adjusted EBITDA* increased 40.7% for the quarter over the prior year period to $15.1 million –

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the second quarter of 2025. The Company’s interim financial statements for the three and six months ended June 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca.

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) --  Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto" or the "Company") is pleased to report operating and financial results for the second quarter of 2025.